UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2015

Vical Incorporated
(Exact name of registrant as specified in its charter)

Delaware	 	
000-21088	 	
93-0948554	
(State or other jurisdiction
of incorporation)	 	(Commission File Number)	 	(IRS Employer
Identification No.)	

10390 Pacific Center Court
San Diego, California	
92121-4340	
(Address of principal executive offices)	(Zip Code)	

Registrant's telephone number, including area code: (858) 646-1100

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
	
 	[   ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 	[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 	[   ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 	[   ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Item 2.02. Results of Operations and Financial Condition.

On October 29, 2015, Vical Incorporated issued a press release announcing, among other things, its unaudited financial results for the three and nine months ended September 30, 2015. A copy of the press release is attached as Exhibit 99.1 to this Current Report.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release issued by Vical Incorporated on October 29, 2015.

SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Vical Incorporated
	
Date: October 29, 2015	By:  	/s/   VIJAY B. SAMANT
Vijay B. Samant
Chief Executive Officer	

INDEX TO EXHIBITS

Exhibit No.	Description	
99.1	Press release issued by Vical Incorporated on October 29, 2015.	

EXHIBIT 99.1
Vical Reports Third Quarter 2015 Financial Results and Progress in Key Development Programs
SAN DIEGO, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three and nine months ended September 30, 2015. Net loss for the third quarter of 2015 was $0.3 million, or $0.00 per share, compared with a net loss of $4.4 million, or $0.05 per share, for the third quarter of 2014. Revenues for the third quarter of 2015 were $5.0 million, compared with revenues of $3.4 million for the third quarter of 2014, reflecting increased revenues from Astellas Pharma Inc. for manufacturing services performed under our ASP0113 collaborative agreements. ASP0113 is Vical's therapeutic vaccine designed to prevent cytomegalovirus (CMV) disease and associated complications in transplant recipients.
Vical generated positive cash flow for the third quarter of 2015 of $0.2 million. The Company had cash and investments of $43.9 million at September 30, 2015 compared to $49.1 million at December 31, 2014. The Company is updating its 2015 full year cash burn guidance to a range of between $7 million and $9 million, a reduction in cash burn from its previous forecast of between $9 million and $12 million.
Program updates include:
ASP0113 CMV Vaccine
·	Enrollment in the multinational Phase 3 registrational trial in approximately 500 hematopoietic cell transplant recipients is ongoing. Astellas has finalized the primary endpoint as a composite of overall mortality and CMV end organ disease and has decided to forego the adaptive trial design. Astellas is in active discussions with regulatory agencies to obtain their concurrence on the selected endpoint. Astellas expects enrollment in the trial to be completed by the third quarter of 2016, with the top-line data being available in the fourth quarter of 2017.
·	Enrollment in the multinational Phase 2 trial in kidney transplant recipients is complete. The primary endpoint of this trial is the incidence of CMV viremia and the study is powered to show an approximately 50% reduction in CMV viremia at one year after transplantation. Top-line trial data are expected to be available in the third quarter of 2016.
HSV-2 Vaccine
·	The subjects in the ongoing Phase 1/2 HSV-2 study will continue to be followed for a period of twelve months for safety and nine months for efficacy following their last dose. Vical expects that additional efficacy data will be available for analysis in December and will enable Vical to determine the next steps for the HSV-2 program by early next year.
VL-2397 Antifungal
·	In August 2015, Vical's novel antifungal, VL-2397, received a qualified infectious disease product, or QIDP, designation from the FDA for the treatment of invasive aspergillosis. Vical is targeting initiation of a Phase 1 trial in the first half of 2016. This will be a randomized, double-blind study to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VL-2397 administered by infusion in healthy volunteers.
Vical will conduct a conference call and webcast today, October 29, at noon Eastern Time, to discuss the Company's financial results and program updates with invited participants. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2376 (preferred), or (888) 401-4669 (toll-free), and reference confirmation code 3993142. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 3993142. The call will also be available live and archived through the events page at www.vical.com. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at ir@vical.com.
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.
Forward-Looking Statements
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include net cash use guidance, as well as anticipated developments in independent and collaborative programs, including the timing of initiation, enrollment and announcement of data for clinical trials. Risks and uncertainties include whether Vical or others will continue development of ASP0113, Vical's HSV-2 vaccine, VL-2397 or any other independent or collaborative programs; whether Vical will achieve levels of revenues and control expenses to meet its financial projections; whether enrollment in on-going trials will continue at current rates; whether Vical or its collaboration partners will be able to obtain regulatory allowances or guidance necessary to proceed with proposed clinical trials or implement anticipated clinical trial designs; whether any product candidates will be shown to be safe and efficacious in clinical trials; whether Vical is able to continue its collaborative arrangements or enter into new ones; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

VICAL INCORPORATED	
Selected Condensed Financial Information (Unaudited)	
 	 	 	 	 	
 	Three Months Ended	Nine Months Ended	
Statements of Operations	September 30,	September 30,	
(in thousands, except per share amounts)	2015	2014	2015	2014	
Revenues:	 	 	 	 	
Contract revenue	$ 4,427	$ 3,004	$ 12,382	$ 9,073	
License and royalty revenue	 590	 438	 1,755	 1,321	
Total revenues	 5,017	 3,442	 14,137	 10,394	
Operating expenses:	 	 	 	 	
Research and development	 2,128	 3,180	 8,222	 7,705	
Manufacturing and production	 1,306	 2,292	 6,626	 7,457	
General and administrative	 1,916	 2,366	 6,271	 7,176	
Total operating expenses	 5,350	 7,838	 21,119	 22,338	
Loss from operations	 (333)	 (4,396)	 (6,982)	 (11,944)	
Net investment and other income	 33	 32	 99	 85	
Net loss	$ (300)	$ (4,364)	$ (6,883)	$ (11,859)	
Basic and diluted net loss per share	$ (0.00)	$ (0.05)	$ (0.08)	$ (0.13)	
Weighted average shares used in computing basic and diluted net loss per share	 91,957	 89,976	 91,600	 88,154	

Balance Sheets	 	 	September 30,	December 31,	
(in thousands)	 	 	2015	2014	
Assets:	 	 	 	 	
Cash, cash equivalents, and marketable securities, including restricted	 	 	$ 41,851	$ 47,152	
Other current assets	 	 	 5,769	 4,178	
Total current assets	 	 	 47,620	 51,330	
Long-term investments	 	 	 2,077	 1,971	
Property and equipment, net	 	 	 2,010	 2,639	
Other assets	 	 	 1,713	 2,039	
Total assets	 	 	$ 53,420	$ 57,979	
 	 	 	 	 	
Liabilities and stockholders' equity:	 	 	 	 	
Current liabilities	 	 	$ 5,474	$ 5,201	
Long-term liabilities	 	 	 494	 856	
Stockholders' equity	 	 	 47,452	 51,922	
Total liabilities and stockholders' equity	 	 	$ 53,420	$ 57,979	
CONTACT: Andrew Hopkins
         Anthony Ramos

         Vice President and Chief Accounting Officer
         (858) 646-1127
         Website: www.vical.com